AlgoMarker™

Home > Products > AlgoMarker™

AlgoMarker™

AlgoMarker™ Clinical Risk Predictors

Medial EarlySign is developing condition-specific, app-like AlgoMarker™ risk predictors for healthcare organizations. These clinical solutions rely upon machine learning to help identify patients at high risk for specific medical conditions . This gives healthcare organizations opportunities for focused and preventative care.

 

The Clinical Rigor Undermining our Model Creation

AlgoMarkers™ are app-like AI clinical risk predictors that support a healthcare organization’s care needs. Our AlgoMarkers™ are meticulously based upon a rigorous, multi-step methodology. The process begins with world leading expert analysis and detailed examination of current methods and treatment guidelines for each disease. It continues to the creation of cohort and outcome registries, the generation of features that enrich the data, rapidly training multiple algorithms using our proprietary database, and concludes with the rigorous evaluation and validation of various data sets.

AlgoMarkers | Clinical Risk Predictors from Medial EarlySign

AlgoMarkers™ Work for Healthcare Organizations

Each condition-specific AlgoMarker™ takes into account multiple potential outcomes, analyzes relevant factors in Electronic Health Records (EHR), and makes condition-specific risk assessment scores using routine patient data. AlgoMarkers work together with our AlgoAnalyzer™ to process patient data between a healthcare organization’s IT infrastructure and our risk predictors. We are currently developing solutions for a variety of medical conditions.

 

ColonFlag™

The company’s first solution, ColonFlag is a decision support software tool that identifies individuals who are at high risk of having colorectal cancer (CRC) by analyzing only conventional blood test results, age and gender. ColonFlag can indicate risks for harboring CRC at its early stages, often months before clinical signs are present.   ColonFlag is implemented at Maccabi Healthcare Services,  where many of the individuals it flagged were later identified as either having CRC or pre-cancerous conditions.  See report of clinical results of first year of implementation and related press coverage

 

ColonFlag bears CE and is not yet cleared by FDA for commercial use in the USA

AlgoMarker

 

AlgoMarker Key Advantages

  • Offer clinically meaningful, condition-specific patient risk predictors
  • Creates timely opportunities for early lifestyle intervention or medial care to potentially delay or prevent illnesses
  • Advanced healthcare IT solution for organizations prioritizing outcome-based and cost-effective patient care

Contact us today to learn details about Medial EarlySign’s AlgoMarker risk predictors.

Download the Study Medial EarlySign MHS ColonFlag™ Case Study